Skip to main content

Advertisement

Table 1 Comparison of results belonging to the study groups at study intervals for the 5 events assessed

From: Effect of the plant-based hemostatic agent Ankaferd Blood Stopper® on the biocompatibility of mineral trioxide aggregate

Histologic events Experimental periods Study groups p
MTA MTA-ABS Control
Inflammatory response (Mean ± SD) 7 days 1 ± 0 1 ± 0 0,75 ± 0,46 0,075
30 days 0 ± 0 0 ± 0 0 ± 0 1,000
60 days 0 ± 0 0 ± 0 0 ± 0 1,000
90 days 0 ± 0 0 ± 0 0 ± 0 1,000
p 0,001 * 0,001 * 0,001 *  
Foreign body reaction (Mean ± SD) 7 days 0,2 ± 0,42 0,3 ± 0,48 0 ± 0 0,262
30 days 0,1 ± 0,32 0,2 ± 0,42 0 ± 0 0,407
60 days 0 ± 0 0,1 ± 0,32 0 ± 0 0,407
90 days 0 ± 0 0 ± 0 0 ± 0 1,000
p 0,276 0,281 1,000  
Fibrosis (Mean ± SD) 7 days 1 ± 0 1,4 ± 0,52 1,25 ± 0,46 0,097
30 days 0,7 ± 0,48 0,4 ± 0,52 0,38 ± 0,52 0,300
60 days 0,1 ± 0,32 0,1 ± 0,32 0,25 ± 0,46 0,603
90 days 0,2 ± 0,42 0,5 ± 0,53 0,75 ± 0,46 0,071
p 0,001 * 0,001 * 0,004 *  
New bone formation (Mean ± SD) 7 days 1,7 ± 0,48 1,6 ± 0,52 1,13 ± 0,35 0,044 ***
30 days 2,3 ± 0,48 2,2 ± 0,42 2,38 ± 0,74 0,681
60 days 2,7 ± 0,48 2,6 ± 0,52 2,25 ± 0,46 0,154
90 days 3 ± 0 3 ± 0 3 ± 0 1,000
p 0,001 * 0,001 * 0,001 *  
Necrosis [n(%)] 7 days 0(%0) 4(%40) 0(%0) 0,024 ***
30 days 0(%0) 0(%0) 0(%0) -
60 days 0(%0) 0(%0) 0(%0) -
90 days 0(%0) 0(%0) 0(%0) -
p - 0,009 ** -  
  1. MTA Mineral trioxide aggregate, ABS Ankaferd blood stopper, SD Standart deviation; *Significant difference within the groups at p < 0.05; **Significant difference within the groups at p < 0.01; ***Significant difference among the groups at p < 0.05; Bold data confines only to p values both within or among the groups